Multi Cancer Early Detection Market - 2026-2035
Multi Cancer Early Detection Marketis is growing with a CAGR of 20.88% during the forecast period 2026-2035.
The Multi Cancer Early Detection Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Multi Cancer Early Detection Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Test Type
Both primary and secondary data sources have been used in the global Multi Cancer Early Detection Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Multi Cancer Early Detection Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Multi Cancer Early Detection Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Test Type
- Liquid Biopsy Tests*
- Gene Panels
- DNA Methylation Tests
- Multi-omics Assays
- Proteomic Biomarker Tests
- Laboratory Developed Tests (LDTs)
- Circulating Tumor DNA Tests
- Circulating Tumor Cell Tests
- Others
- Next Generation Sequencing*
- Next Generation Sequencing
- Targeted Sequencing
- Fragmentomics
- Epigenomics
- Proteomics
- Transcriptomics
- Artificial Intelligence Based Signal Analysis
- Machine Learning Pattern Recognition
- Bioinformatics Algorithms
- Others
- Blood*
- Plasma
- Serum
- Saliva or Buccal Swab
- Urine
- Tissue
- Cerebrospinal Fluid
- Others
- Breast Cancer*
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Gastric Cancer
- Blood Cancer
- Others
- Out-of-Pocket*
- Insurance Covered
- Employer Sponsored
- Government or Public Screening Programs
- Reimbursed Testing*
- Non-Reimbursed Testing
- Partial Reimbursement
- Value-Based Reimbursement
- Hospitals and Clinics*
- Diagnostic Laboratories
- Specialty Cancer Centers
- Academic and Research Institutes
- Reference Laboratories
- Preventive Health Screening Providers
- Direct-to-Consumer Testing Providers
- Home Collection and Digital Screening Platforms
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Multi Cancer Early Detection Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Expansion of AI and Multi-Omics Applications in Cancer Detection
4.1.1.2. Growing Adoption of Blood-Based Multi-Cancer Screening Platforms
4.1.1.3. Expansion of Large-Scale Clinical Trials and Population Screening Programs
4.1.2. Restraints
4.1.2.1. Technical Challenges in Detecting Low Tumor Signal in Early-Stage Cancers
4.1.2.2. Complex Clinical Validation Requirements for Multi-Cancer Screening Tests
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Expansion Potential in Average-Risk Population Screening Programs
4.1.4.2. Integration of Multi-Cancer Early Detection Tests into Preventive Health Checkup Pathways
4.1.5. Trends
4.1.5.1. Shift Toward Methylation-Based and Fragmentomics-Driven Test Development
4.1.5.2. Rising Strategic Collaborations Between Diagnostic Developers, Health Systems, and Research Networks
4.1.6. Challenges
4.1.6.1. Limited Reimbursement Clarity and Uncertain Screening Pathway Integration
4.1.6.2. Risk of False Positives and Complexity in Determining Cancer Signal Origin
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Forces Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Growing acceptance of minimally invasive blood-based cancer screening among patients.
5.3.2. Awareness of early cancer detection benefits influences preventive healthcare participation.
5.3.3. Physician confidence depends on clinical validation, diagnostic accuracy, and false-positive management.
5.4. Economic Factors
5.4.1. High per-test cost requires evidence of downstream healthcare savings through early detection.
5.4.2. Reimbursement clarity significantly impacts commercialization and patient accessibility.
5.4.3. Strategic payer partnerships are critical for scaling population-based screening adoption.
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY TEST TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Liquid Biopsy Tests*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Gene Panels
6.4. DNA Methylation Tests
6.5. Multi-omics Assays
6.6. Proteomic Biomarker Tests
6.7. Laboratory Developed Tests (LDTs)
6.8. Circulating Tumor DNA Tests
6.9. Circulating Tumor Cell Tests
6.10. Others
7. BY TECHNOLOGY
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Next Generation Sequencing*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next Generation Sequencing
7.4. Targeted Sequencing
7.5. Fragmentomics
7.6. Epigenomics
7.7. Proteomics
7.8. Transcriptomics
7.9. Artificial Intelligence Based Signal Analysis
7.10. Machine Learning Pattern Recognition
7.11. Bioinformatics Algorithms
7.12. Others
8. BY SAMPLE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
8.1.2. Market Attractiveness Index, By Sample Type
8.2. Blood*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Plasma
8.4. Serum
8.5. Saliva or Buccal Swab
8.6. Urine
8.7. Tissue
8.8. Cerebrospinal Fluid
8.9. Others
9. BY CANCER TYPE
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type
9.2. Breast Cancer*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Lung Cancer
9.4. Colorectal Cancer
9.5. Prostate Cancer
9.6. Liver Cancer
9.7. Ovarian Cancer
9.8. Pancreatic Cancer
9.9. Gastric Cancer
9.10. Blood Cancer
9.11. Others
10. BY PAYMENT MODEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Payment Model
10.1.2. Market Attractiveness Index, By Payment Model
10.2. Out-of-Pocket*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Insurance Covered
10.4. Employer Sponsored
10.5. Government or Public Screening Programs
11. BY REIMBURSEMENT MODEL
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Reimbursement Model
11.1.2. Market Attractiveness Index, By Reimbursement Model
11.2. Reimbursed Testing*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Non-Reimbursed Testing
11.4. Partial Reimbursement
11.5. Value-Based Reimbursement
12. BY END-USER
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Hospitals and Clinics*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Diagnostic Laboratories
12.4. Specialty Cancer Centers
12.5. Academic and Research Institutes
12.6. Reference Laboratories
12.7. Preventive Health Screening Providers
12.8. Direct-to-Consumer Testing Providers
12.9. Home Collection and Digital Screening Platforms
12.10. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America*
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.8.1. Germany
13.3.8.2. UK
13.3.8.3. France
13.3.8.4. Russia
13.3.8.5. Spain
13.3.8.6. Italy
13.3.8.7. Poland
13.3.8.8. Rest of Europe
13.4. Latin America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.8.1. Brazil
13.4.8.2. Argentina
13.4.8.3. Rest of Latin America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.8.1. China
13.5.8.2. India
13.5.8.3. Japan
13.5.8.4. Australia
13.5.8.5. South Korea
13.5.8.6. Indonesia
13.5.8.7. Malaysia
13.5.8.8. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.6.8.1. UAE
13.6.8.2. Saudi Arabia
13.6.8.3. South Africa
13.6.8.4. Israel
13.6.8.5. Turkiye
13.6.8.6. Rest of Middle East and Africa
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline
15. COMPANY PROFILES
15.1. GRAIL, Inc*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Revenue Analysis
15.1.4. Pricing Analysis
15.1.5. SWOT Analysis
15.1.6. Recent Developments
15.1.6.1. Major Deals
15.1.6.2. M&A
15.1.6.3. Collaboration
15.1.6.4. Acquisition
15.1.6.5. Joint Ventures
15.1.6.6. Innovations
15.1.7. Recent News
15.1.7.1. Events
15.1.7.2. Conferences
15.1.7.3. Symposiums
15.1.7.4. Webinars
15.2. Exact Sciences Corporation
15.3. Burning Rock Dx
15.4. Guardant Health, Inc
15.5. Freenome Holdings, Inc.
15.6. Singlera Genomics Inc.
15.7. SeekIn Inc.
15.8. Illumina, Inc
15.9. Foundation Medicine, Inc.
15.10. Natera, Inc. (LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Expansion of AI and Multi-Omics Applications in Cancer Detection
4.1.1.2. Growing Adoption of Blood-Based Multi-Cancer Screening Platforms
4.1.1.3. Expansion of Large-Scale Clinical Trials and Population Screening Programs
4.1.2. Restraints
4.1.2.1. Technical Challenges in Detecting Low Tumor Signal in Early-Stage Cancers
4.1.2.2. Complex Clinical Validation Requirements for Multi-Cancer Screening Tests
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Expansion Potential in Average-Risk Population Screening Programs
4.1.4.2. Integration of Multi-Cancer Early Detection Tests into Preventive Health Checkup Pathways
4.1.5. Trends
4.1.5.1. Shift Toward Methylation-Based and Fragmentomics-Driven Test Development
4.1.5.2. Rising Strategic Collaborations Between Diagnostic Developers, Health Systems, and Research Networks
4.1.6. Challenges
4.1.6.1. Limited Reimbursement Clarity and Uncertain Screening Pathway Integration
4.1.6.2. Risk of False Positives and Complexity in Determining Cancer Signal Origin
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Forces Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Growing acceptance of minimally invasive blood-based cancer screening among patients.
5.3.2. Awareness of early cancer detection benefits influences preventive healthcare participation.
5.3.3. Physician confidence depends on clinical validation, diagnostic accuracy, and false-positive management.
5.4. Economic Factors
5.4.1. High per-test cost requires evidence of downstream healthcare savings through early detection.
5.4.2. Reimbursement clarity significantly impacts commercialization and patient accessibility.
5.4.3. Strategic payer partnerships are critical for scaling population-based screening adoption.
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY TEST TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
6.1.2. Market Attractiveness Index, By Test Type
6.2. Liquid Biopsy Tests*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Gene Panels
6.4. DNA Methylation Tests
6.5. Multi-omics Assays
6.6. Proteomic Biomarker Tests
6.7. Laboratory Developed Tests (LDTs)
6.8. Circulating Tumor DNA Tests
6.9. Circulating Tumor Cell Tests
6.10. Others
7. BY TECHNOLOGY
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
7.1.2. Market Attractiveness Index, By Technology
7.2. Next Generation Sequencing*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next Generation Sequencing
7.4. Targeted Sequencing
7.5. Fragmentomics
7.6. Epigenomics
7.7. Proteomics
7.8. Transcriptomics
7.9. Artificial Intelligence Based Signal Analysis
7.10. Machine Learning Pattern Recognition
7.11. Bioinformatics Algorithms
7.12. Others
8. BY SAMPLE TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
8.1.2. Market Attractiveness Index, By Sample Type
8.2. Blood*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Plasma
8.4. Serum
8.5. Saliva or Buccal Swab
8.6. Urine
8.7. Tissue
8.8. Cerebrospinal Fluid
8.9. Others
9. BY CANCER TYPE
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
9.1.2. Market Attractiveness Index, By Cancer Type
9.2. Breast Cancer*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Lung Cancer
9.4. Colorectal Cancer
9.5. Prostate Cancer
9.6. Liver Cancer
9.7. Ovarian Cancer
9.8. Pancreatic Cancer
9.9. Gastric Cancer
9.10. Blood Cancer
9.11. Others
10. BY PAYMENT MODEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Payment Model
10.1.2. Market Attractiveness Index, By Payment Model
10.2. Out-of-Pocket*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Insurance Covered
10.4. Employer Sponsored
10.5. Government or Public Screening Programs
11. BY REIMBURSEMENT MODEL
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Reimbursement Model
11.1.2. Market Attractiveness Index, By Reimbursement Model
11.2. Reimbursed Testing*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Non-Reimbursed Testing
11.4. Partial Reimbursement
11.5. Value-Based Reimbursement
12. BY END-USER
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Hospitals and Clinics*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Diagnostic Laboratories
12.4. Specialty Cancer Centers
12.5. Academic and Research Institutes
12.6. Reference Laboratories
12.7. Preventive Health Screening Providers
12.8. Direct-to-Consumer Testing Providers
12.9. Home Collection and Digital Screening Platforms
12.10. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America*
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.8.1. Germany
13.3.8.2. UK
13.3.8.3. France
13.3.8.4. Russia
13.3.8.5. Spain
13.3.8.6. Italy
13.3.8.7. Poland
13.3.8.8. Rest of Europe
13.4. Latin America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.8.1. Brazil
13.4.8.2. Argentina
13.4.8.3. Rest of Latin America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.8.1. China
13.5.8.2. India
13.5.8.3. Japan
13.5.8.4. Australia
13.5.8.5. South Korea
13.5.8.6. Indonesia
13.5.8.7. Malaysia
13.5.8.8. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sample Type
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
13.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.6.8.1. UAE
13.6.8.2. Saudi Arabia
13.6.8.3. South Africa
13.6.8.4. Israel
13.6.8.5. Turkiye
13.6.8.6. Rest of Middle East and Africa
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline
15. COMPANY PROFILES
15.1. GRAIL, Inc*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Revenue Analysis
15.1.4. Pricing Analysis
15.1.5. SWOT Analysis
15.1.6. Recent Developments
15.1.6.1. Major Deals
15.1.6.2. M&A
15.1.6.3. Collaboration
15.1.6.4. Acquisition
15.1.6.5. Joint Ventures
15.1.6.6. Innovations
15.1.7. Recent News
15.1.7.1. Events
15.1.7.2. Conferences
15.1.7.3. Symposiums
15.1.7.4. Webinars
15.2. Exact Sciences Corporation
15.3. Burning Rock Dx
15.4. Guardant Health, Inc
15.5. Freenome Holdings, Inc.
15.6. Singlera Genomics Inc.
15.7. SeekIn Inc.
15.8. Illumina, Inc
15.9. Foundation Medicine, Inc.
15.10. Natera, Inc. (LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
